---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-032859"
form_type: "8-K"
ticker: "KALV"
cik: "0001348911"
company_name: "KalVista Pharmaceuticals, Inc."
filed_at: "2024-02-13T23:59:59+00:00"
generated_at: "2026-06-06T03:13:43.087209+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# KalVista announces positive Phase 3 KONFIDENT results; sebetralstat meets all endpoints with rapid symptom relief

## Summary
- Sebetralstat 300 mg achieved beginning of symptom relief in median 1.61 hours vs placebo 6.72 hours (p<0.0001).
- Trial met all primary and key secondary endpoints; no treatment-related SAEs and no withdrawals due to AEs.
- Treatment-related adverse event rates: 2.3% for 300 mg, 2.2% for 600 mg, 4.8% for placebo.
- Plan to submit NDA to U.S. FDA in first half of 2024 and in EU and Japan later in 2024.
- Largest HAE trial ever with 136 patients from 66 sites across 20 countries.

## SEC filing metadata
- accession: 0001193125-24-032859
- form_type: 8-K
- ticker: KALV
- cik: 0001348911
- company_name: KalVista Pharmaceuticals, Inc.
- filed_at: 2024-02-13T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1348911/000119312524032859/0001193125-24-032859-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1348911/000119312524032859/d785380d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-032859
- JSON: https://secwatch.observer/filing/0001193125-24-032859.json
- Plain text: https://secwatch.observer/filing/0001193125-24-032859.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.